Replies to post #42743 on Zhong Nong Yuan Fang Holdings Inc (ANAS)

[Potse]

ANAS...pre-IPO private equity roadshow.....

I have been adding heavily to my position at these sub-2 cent prices. Current cost basis is under .0122, with about half those shares qualifying for long-term capital gains. Risk/reward looks interesting to me with potential catalysts approaching. According to Aaron Tsai's social media accounts (Instagram, X, Facebook), ANAS will be having its first pre-IPO private equity roadshow event next week (December 19). Translation of the graphic that accompanies his posts......

Its subsidiary, "Xi'an Lian'er Technology," is the first high-tech enterprise in mainland China to be approved by the National Medical Products Administration (NMPA) for using biochips in clinical diagnostics.

Deeply involved in medium-to-low-density protein biofiltration chip technology, currently holding a market share of up to 60% in this field in mainland China, with over 1,000 terminal hospital clients.

Independent intellectual property rights: 11 national patents (3 invention patents, 7 utility model patents, 1 design patent) and 5 software copyrights.

Tuberculosis urine screening reagent: The only product in mainland China and globally that can rapidly detect the LAM antigen, possessing huge potential for development into a home self-testing market.

Multi-indicator combined testing reagents: Such as cervical cancer five-in-one test, eugenics five-in-one test, infertility six-in-one test, Helicobacter pylori test, respiratory seven-in-one test, and brucellosis four-in-one test, all of which are fast, accurate, low-cost, and have been included in mainland China's medical insurance coverage.

https://www.instagram.com/p/DR4Cy44AdcN/

https://x.com/AaronTsaiMASFi/status/1996865264458387611

[Stonewallet]

Good information, thanks. I have established a decently-strong starter position here at these price levels. Really like the existing share structure, with only an 11 million share float. However, considering this share structure in combination with the news of ANAS bringing in MAS to facilitate an uplisting, wouldn't a R/S be the likely vehicle used to get the SP up to those levels....barring the release of some terrific announcement or financials, of course? That would certainly damper any enthusiasm. After many years of doing this, I've yet to see a R/S benefit my portfolio in the long run.